(Q36689490)

15 August 2017

1 reference

title

Anti-infective research and development--problems, challenges, and solutions (English)

1 reference

15 August 2017

6

George G Zhanel

1 reference

15 August 2017

John S Bradley

1

1 reference

15 August 2017

Robert Guidos

2

1 reference

15 August 2017

Steve Baragona

3

1 reference

15 August 2017

John G Bartlett

4

1 reference

15 August 2017

Ethan Rubinstein

5

1 reference

15 August 2017

Michael D Tino

7

1 reference

15 August 2017

David L Pompliano

8

1 reference

15 August 2017

Frank Tally

9

1 reference

15 August 2017

Praveen Tipirneni

10

1 reference

15 August 2017

Glenn S Tillotson

11

1 reference

15 August 2017

John H Powers

12

1 reference

15 August 2017

Glenn S Tillotson

13

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Lancet Infectious Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

68-78

1 reference

Trends in antimicrobial drug development: implications for the future

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Treatment of ventilator-associated pneumonia: get it right from the start.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Nosocomial infections caused by Acinetobacter baumannii: a major threat worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Single-dose azithromycin for the treatment of cholera in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Antimicrobial drug resistance, regulation, and research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Adopting orphan drugs--two dozen years of treating rare diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Protecting the health of the public--Institute of Medicine recommendations on drug safety.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970689-2

7 January 2021

10.1016/S1473-3099(06)70689-2

Identifiers

DOI

1 reference

release_pogkqjawgra3jomk5hceksm4iu

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pogkqjawgra3jomk5hceksm4iu

24 November 2022

mapped directly with Wikidata item

1 reference